Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, UK.
Department of Pathomorphology and Molecular Diagnostics, Medical University of Silesia, Katowice, Poland.
Mol Oncol. 2024 Mar;18(3):677-690. doi: 10.1002/1878-0261.13576. Epub 2024 Jan 3.
The median age of patients with pancreatic ductal adenocarcinoma (PDAC) at diagnosis is 71 years; however, around 10% present with early-onset pancreatic cancer (EOPC), i.e., before age 50. The molecular mechanisms underlying such an early onset are unknown. We assessed the role of common PDAC drivers (KRAS, TP53, CDKN2A and SMAD4) and determined their mutational status and protein expression in 90 formalin-fixed, paraffin-embedded tissues, including multiple primary and matched metastases, from 37 EOPC patients. KRAS was mutated in 88% of patients; p53 was altered in 94%, and p16 and SMAD4 were lost in 86% and 71% of patients, respectively. Meta-synthesis showed a higher rate of p53 alterations in EOPC than in late-onset PDAC (94% vs. 69%, P = 0.0009) and significantly higher loss of SMAD4 (71% vs. 44%, P = 0.0025). The majority of EOPC patients accumulated aberrations in all four drivers; in addition, high tumour heterogeneity was observed across all tissues. The cumulative effect of an exceptionally high rate of alterations in all common PDAC driver genes combined with high tumour heterogeneity suggests an important mechanism underlying the early onset of PDAC.
胰腺导管腺癌 (PDAC) 患者的中位诊断年龄为 71 岁;然而,约有 10%的患者表现为早发性胰腺癌 (EOPC),即发病年龄在 50 岁之前。这种早发的分子机制尚不清楚。我们评估了常见的 PDAC 驱动因素(KRAS、TP53、CDKN2A 和 SMAD4)的作用,并在 37 名 EOPC 患者的 90 份福尔马林固定、石蜡包埋组织中确定了它们的突变状态和蛋白表达情况,包括多个原发性和匹配的转移灶。88%的患者存在 KRAS 突变;94%的患者存在 p53 改变,p16 和 SMAD4 分别有 86%和 71%的患者缺失。荟萃分析显示,EOPC 中 p53 改变的发生率高于晚发性 PDAC(94% vs. 69%,P=0.0009),SMAD4 的缺失率显著更高(71% vs. 44%,P=0.0025)。大多数 EOPC 患者在所有四个驱动基因中都积累了异常;此外,所有组织中均观察到高肿瘤异质性。所有常见 PDAC 驱动基因的异常改变率异常高加上肿瘤异质性高,这表明了 PDAC 早发的一个重要机制。